OOIR: Observatory of International Research

Papers

(The H4-Index of npj Vaccines is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice	528
Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines	270
Antibody enhanced HPLC for serotype-specific quantitation of polysaccharides in pneumococcal conjugate vaccine	200
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern	200
Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza	173
Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets	126
Insights into the protective immune response by immunization with full-length recombinant TprK protein: cellular and humoral responses	118
The full health, economic, and social benefits of prospective Strep A vaccination	117
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI	115
BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice	97
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys	86
No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines	86
A protein subunit vaccine elicits a balanced immune response that protects against Pseudomonas pulmonary infection	84
Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform	82
Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques	81
Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination	70
Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein	68
Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice	64
Efficacy and safety in mice of repeated, lifelong administration of an ANGPTL3 vaccine	63
PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application	62
Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis	58
Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore	55
Risk assessment of retinal vascular occlusion after COVID-19 vaccination	55
Evaluation of adenoviral vector Ad19a encoding RSV-F as novel vaccine against respiratory syncytial virus	52
Cross-protection and cross-neutralization capacity of ancestral and VOC-matched SARS-CoV-2 adenoviral vector-based vaccines	51

Assessing immunogenicity barriers of the HIV-1 envelope trimer	50
Adverse effects, perceptions and attitudes related to BNT162b2, mRNA-1273 or JNJ-78436735 SARS-CoV-2 vaccines: Population-based cohort	50
Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens	48
A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2	47
Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine	47
Protein engineering strategies for rational immunogen design	47
Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study	46
Identification of the flavivirus conserved residues in the envelope protein hinge region for the rational design of a candidate West Nile live-attenuated vaccine	45
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year	45
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine	43
Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses	41
Duck CD40L as an adjuvant enhances systemic immune responses of avian flavivirus DNA vaccine	40
YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge	40
Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice	39
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants	39
Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines	39
Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model	39